Allogene Therapeutics Stock Price on November 23, 2024
| ALLO Stock | USD 2.52 0.24 10.53% |
Below is the normalized historical share price chart for Allogene Therapeutics extending back to October 11, 2018. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Allogene Therapeutics stands at 2.52, as last reported on the 27th of November, with the highest price reaching 2.77 and the lowest price hitting 2.44 during the day.
If you're considering investing in Allogene Stock, it is important to understand the factors that can impact its price. As of now, Allogene Stock is relatively risky. Allogene Therapeutics secures Sharpe Ratio (or Efficiency) of 0.01, which signifies that the company had a 0.01% return per unit of risk over the last 3 months. We have found twenty-four technical indicators for Allogene Therapeutics, which you can use to evaluate the volatility of the firm. Please confirm Allogene Therapeutics' Risk Adjusted Performance of 0.0053, standard deviation of 5.31, and Mean Deviation of 4.31 to double-check if the risk estimate we provide is consistent with the expected return of 0.0531%.
At this time, Allogene Therapeutics' Total Stockholder Equity is very stable compared to the past year. As of the 27th of November 2024, Liabilities And Stockholders Equity is likely to grow to about 695.7 M, while Common Stock Total Equity is likely to drop about 121.7 K. . At this time, Allogene Therapeutics' Price To Sales Ratio is very stable compared to the past year. As of the 27th of November 2024, Price Book Value Ratio is likely to grow to 1.03, while Price Earnings Ratio is likely to drop (1.62). Allogene Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 11th of October 2018 | 200 Day MA 3.0992 | 50 Day MA 2.677 | Beta 0.836 |
Allogene |
Sharpe Ratio = 0.01
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | ALLO | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.32 actual daily | 47 53% of assets are more volatile |
Expected Return
| 0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Allogene Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Allogene Therapeutics by adding Allogene Therapeutics to a well-diversified portfolio.
Price Book 1.0308 | Enterprise Value Ebitda (1.04) | Price Sales 12.3 K | Shares Float 151.9 M | Wall Street Target Price 9.0417 |
Allogene Therapeutics Main Headline on 22nd of November 2024
REPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead candidate, RP1, in combination with Opdivo for advanced melanoma.
Allogene Therapeutics Valuation on November 23, 2024
It is possible to determine the worth of Allogene Therapeutics on a given historical date. On November 23, 2024 Allogene was worth 2.12 at the beginning of the trading date compared to the closed value of 2.21. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Allogene Therapeutics stock. Still, in general, we apply an absolute valuation method to find Allogene Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Allogene Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Allogene Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 2.06 | 2.14 | 2.01 | 2.11 | 1,895,528 | |
11/22/2024 | 2.12 | 2.23 | 2.09 | 2.21 | 1,433,020 |
| 2.26 | 2.36 | 2.23 | 2.28 | 3,957,489 |
| Backtest Allogene Therapeutics | | | Allogene Therapeutics History | | | Allogene Therapeutics Valuation | Previous | Next |
Allogene Therapeutics Trading Date Momentum on November 23, 2024
| On November 25 2024 Allogene Therapeutics was traded for 2.28 at the closing time. The top price for the day was 2.36 and the lowest listed price was 2.23 . The trading volume for the day was 4 M. The trading history from November 25, 2024 was a factor to the next trading day price boost. The overall trading delta against the next closing price was 3.17% . The overall trading delta against the current closing price is 13.57% . |
Allogene Therapeutics Fundamentals Correlations and Trends
By evaluating Allogene Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Allogene Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Allogene financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Allogene Therapeutics Stock history
Allogene Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Allogene is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Allogene Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Allogene Therapeutics stock prices may prove useful in developing a viable investing in Allogene Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 156.9 M | 125.7 M | |
| Net Loss | -299.4 M | -314.3 M |
Allogene Therapeutics Quarterly Net Working Capital |
|
Allogene Therapeutics Stock Technical Analysis
Allogene Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Allogene Therapeutics Period Price Range
Low | November 27, 2024
| High |
0.00 | 0.00 |
Allogene Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Allogene Therapeutics November 27, 2024 Market Strength
Market strength indicators help investors to evaluate how Allogene Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Allogene Therapeutics shares will generate the highest return on investment. By undertsting and applying Allogene Therapeutics stock market strength indicators, traders can identify Allogene Therapeutics entry and exit signals to maximize returns
Allogene Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Allogene Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Allogene Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Allogene to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0053 | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.87) | |||
| Treynor Ratio | (0.01) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Quarterly Revenue Growth (0.27) | Return On Assets (0.26) | Return On Equity (0.54) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.